For screening of new glyco-PSs to be used in cancer PDT [6, 10, 58], the overarching hypothesis is that these dyes adhere to glyco-binding proteins such as galectin-1 and GLUT1 overexpressed in cancer cells, thereby improving the selectivity of the PS for cancer. This evidence concerns the gene SLC2A1 and cancer.